Complete Loss of HLA Class I Heterozygosity in a Patient with Acute Myeloid Leukemia  by Zollikofer, Christine et al.
Table 1









Group 1 2 (18%) 6 (55%) 11
Group 2 12 (34%) 25 (71%) 35
Group 3 74 (63%) 114 (97%) 117
Total 88 (54%) 145 (89%) 163
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170 S161To prevent life-threatening encephalitis associated with
HHV-6 reactivation following SCT, we weekly examined
plasma HHV-6 DNA loads using real-time quantitative-po-
lymerase chain reaction methods until ﬁve weeks post-SCT
in 11 unrelated umbilical cord blood transplantation (CBT)
and 42 unmanipulated HLA-mismatched/haploidentical
related SCT (haplo-SCT).
CBT recipients were conditioned with cytarabine 12 g/m2,
cyclophosphamide 120 mg/kg, and total body irradiation
(TBI) 12 Gy as a myeloablative regimen and ﬂudarabine 200
mg/m2, cyclophosphamide 50 mg/kg, and TBI 3 Gy for a
reduced-intensity regimen. Prophylaxis for graft-versus-host
disease (GVHD) consisted of cyclosporine A, with myco-
phenolate mofetil (MMF) or a short course of methotrexate
(sMTX).
Haplo-SCT recipients were conditioned with ﬂudarabine
120 mg/m2, cytarabine 8 g/m2, cyclophosphamide 120
mg/kg, and TBI 8e12 Gy for a myeloablative regimen and
ﬂudarabine 180 mg/m2, rabbit ATG 8 mg/kg (Fresenius,
Munich, Germany) or 4 mg/kg (Genzyme, Tokyo, Japan), and
busulfan 8 mg/kg or melphalan for a reduced-intensity
regimen. Bone marrow and peripheral blood stem cells were
infused freshly without T-cell depletion. GVHD prophylaxis
against myeloablative and reduced-intensity haplo-SCT was
performed with tacrolimus, sMTX, MMF, and methylpred-
nisolone 2 mg/kg, and tacrolimus and methylprednisolone 1
mg/kg, respectively.
Compared to all of 11 CBT recipients (100%), plasma HHV-
6 DNA was detected in 3 of 42 haplo-SCT recipients (7.1%)
despite methylprednisolone use for graft-versus-host dis-
ease prophylaxis. As preemptive therapy, 8 CBT and 3 haplo-
SCT recipients were administered foscarnet or ganciclovir at
a median of four days (range, 0 to 9) after detection of HHV-6
DNA, followed by its rapid resolution except for one CBT
recipient who had repeatedly positive results. The remaining
3 CBT recipients were administered foscarnet before detec-
tion of plasma HHV-6 DNA. Despite HHV-6 reactivation, no
patients developed HHV-6-associated encephalitis.
In the present observations both HLA disparity, and the
use of methylprednisolone and antithymocyte globulin
was not necessarily a risk factor for development of HHV-6
reactivation in our haplo-SCT fashion. Furthermore,
preemptive or prophylactic administration of antivirals
potentially prevents HHV-6-associated encephalitis by
suppression of HHV-6 reactivation at an early stage of SCT.197
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Recent research suggests that beyond 8/8 allele level
matching at HLA-A, B, C, DRB1,matching at HLA-DPB1 should
be considered to improve patient survival rates in allogeneic
stem cell transplantation. DPB1 alleles have been separated
into three T-cell epitope (TCE) groups based on reactivity in
functional assays for matching: 1) high 2) intermediate 3)
low immunogenic potential. Non-permissive TCEmismatches at DPB1 are associated with a higher incidence
of transplant related mortality in patients that have a 10/10
matched donor.
We performed a study to identify the likelihood of having a
DPB1 permissive TCE matched donor for patients with 10/10
high resolution matched donor options (HapLogic predic-
tion of 75%) in the Be The Match Registry. 163 patient
searches from US transplant centers that submitted a pre-
liminary search request with DPB1 typing were evaluated for
DPB1 TCE permissive mismatched donors, either identiﬁed
through existing registry typing or by prospectively typing
up to 10 donors per patient.
88 of 163 patient searches had a DPB1 TCE permissive
mismatch present on the initial search results, 11 patient
searches did not have a potential DPB1 matched donor, and
the remaining 64 patient searches had up to 10 donors per
patient selected for DPB1 typing, prioritizing young male
donors. 57 out of 64 patients were able to ﬁnd a DPB1 TCE
permissive match via donor typing resulting in an overall
TCE permissive match rate of 89%. Table 1 shows the
condensed TCE groups of the patients assessed in the study,
with patients being classiﬁed by their highest immunogenic
TCE reactivity (i.e. 1>2>3). On initial donor search results,
patients carrying any DPB1 TCE group 1 allele found a match
18% of the time, 34% for group 2 and 63% for group 3. Typing
donors signiﬁcantly improved the identiﬁcation of a DPB1
permissive mismatched donor for all 3 groups to 55% for TCE
group 1, 71% group 2 and 97% for group 3.
This study selection process focused on patients with more
productive searches and shows that identifying a DPB1 TCE
permissive matched donor in these cases is likely for the
majority of patients. HLA typing donors who are predicted to
be 10/10 matches for HLA-DPB1 may provide a feasible
strategy for optimizing donor selection regardless of patient
TCE group.198
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Loss of heterozygosity (LOH) for certain HLA class I alleles
provides tumor cells with an efﬁcient mechanism to escape
the T cell immune response. Here we report a case of com-
plete class I LOH in a patient suffering from acute myeloid
leukemia, which was associated with an intriguing HLA-
typing procedure. The patient was diagnosed with AML FAB
M1 and further analysis revealed a nucleophosmin1 (NPM1)
mutation and normal male karyotype 46XY.
In February 2013 two independently collected EDTA blood
samples (S1 + S2) arrived at our lab for HLA testing. Primary
HLA class I and II typing was done for S1 with Sanger
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ciﬁc oligonucleotide primed PCR (PCR-SSO). Both methods
showed a homozygous phenotype for HLA class I loci (A, B, C)
and heterozygosity for HLA class II alleles (DRB1,DQB1). After
consolidation, increasing minimal residual disease (MRD)
measured by a close NPM1, monitoring was observed in
September 2013 and the patient was scheduled for an allo-
geneic stem cell transplantation. No blasts were present in
the peripheral blood of the patient at the time point of mo-
lecular relapse. To initiate search for an unrelated donor a
conﬁrmatory patient HLA-typing was performed. Due to
poor S2 DNA quality a new blood sample (S3) was ordered
and used for secondary typing. Whereas HLA class II results
were consistent, SBT and PCR-SSO showed discrepant class I
typing results when compared to S1, with heterozygosity for
all three loci. Consultation of the transplantation center
revealed that S1 + S2 were taken while the patient had 84%
blasts in the peripheral blood. Heterozygous patient HLA
status was ﬁnally conﬁrmed by typing of a saliva sample (S4)
with SBT and SSO-PCR, respectively. According to the infor-
mation about S1 (primary diagnosis, peripheral blasts), S3
(increasing MRD, no peripheral blasts) and S4 (blast free
material) we assumed that in S1 cells with somatic HLA class
I phenotype were highly outnumbered by blasts bearing a
complete class I LOH.
In regard to this casewestrongly recommend conﬁrmatory
typing to be carried out on blast free samples only, or by using
a highly sensitive PCR-SSP in case of a substantial amount of
blasts in the blood. This should help to prevent the otherwise
potentially fatal selection of a highly mismatched donor. As a
consequence we established a routinely feedback on the pe-
ripheral blast status of the sample on our test request form.IMMUNE RECONSTITUTION
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Background: CD34+ and CD3 cell-doses given during autol-
ogous stem cell transplantation (ASCT) can vary between
patients (pts) depending on ability to mobilize and cell
collection method. Retrospective studies suggest that im-
mune recovery and absolute lymphocyte count (ALC) may be
a predictor of overall survival (OS), progression free survival
(PFS), and infectious complications in ASCT. However, It is
unclear whether there is an optimal CD34+ or CD3 cell-dose
that correlates with better outcomes.
Methods: A retrospective analysis of the immune recovery
was performed on 24 consecutive lymphoma pts who had
undergone ASCT from 1/2012 to 6/2014 at the University of
Virginia to determine if a relationship existed between
CD34+ or CD3 cell-dose given during ASCT and immune re-
covery. For each pt, number/type of infections, IgG level, T
cell counts (CD4 and CD8), and ALC were collected for the
ﬁrst 100 days post-ASCT. OS and PFS were also assessed for
each pt. Cox proportional hazard models were used to esti-
mate the association of cell-dose infused with time to count
recovery after ASCT.Results: Median age was 57 years (range from 28-69 years),
and 62% were male. Lymphoma subtypes were 62% B cell
lymphoma, 21% Hodgkin and 17% systemic T cell. All Pts were
with advance stages and heavily pretreated (median 2 lines).
Peripheral blood stem cell grafts had a median CD34 of
6.2x10
ˇ
6, TNC of 10.9 x10
ˇ
8, and T cells of 154 x10
ˇ
6. Almost
half of the pts (n¼11) were mobilized with plerixafor with no
chemotherapy.Median followupwas 417days (102-763). The
analysis revealed that a higher CD34+ cell-dose given was
signiﬁcantly (p<0.05) associated with higher IgG at day 30
and earlier platelet recovery (>50,000). Higher T cell dose
(>150x106) was also associated with higher IgG level at day
30, but unlike CD34dose, CD3was associatedwith higherALC
(>1000 cells/microL) at day 100 (p<0.05). Due to sample size
and different disease associated risk factors, effect of cells
dose on relapsewas not statistically signiﬁcant. Infection rate
(almost half of pts) was similar in high vs. low cell dose. Most
of the infections were bacterial and happened early post
transplant with the exception of two cases of inﬂuenza and
CMV. Pts who were mobilized with plerixafor without
chemotherapy had a higher dose of CD3 collected compare to
pts mobilized with chemotherapy (239 vs. 113. P¼0.056).
Conclusion: These preliminary results suggest that CD3+
cell-dose > 150x106 cells/kg given during ASCT for aggres-
sive lymphoma may be associated with not only better early
IgG level and but also with better ALC. However, larger
prospective trials are necessary to further deﬁne optimal CD3
and CD34+ cell-dose infusion for ASCT in lymphoma pts in
order to improve immune recovery and prevent relapse.200
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Introduction: Bacterial bloodstream infections (BBSIs)
contribute signiﬁcantly to transplant relatedmortality (TRM)
post allogeneic hematopoietic cell transplant (alloHCT). In
2006, a new central-line associated bloodstream infection
(CLABSI) protocol was established at our institution. We
report the incidence rate and sensitivities of both Gram
negative rod (GNR) and Gram positive cocci (GPC) BBSIs
during Pre-CLABSI era (2004-06), CLABSI era (2006-10), and
post-CLABSI era (2010-13).
Methods: A retrospective chart review between 2004-2013
was conducted. 100 person-month bacterial infection
incidences were calculated and compared by Poisson
regression analysis. Patients did not receive prophylactic
anti-bacterial antibiotics and piperacillin/tazobactam was
started at the onset of fever.
Results: Between 2004-13, 302 BBSIs were identiﬁed in 190
patients (mean age 9.97 years). Malignant 111 (58.4%), Non-
malignant 79 (41.6%); donor source: Marrow 71 (37.4%), Pe-
ripheral Blood Stem Cell 59 (31.1%), Cord blood 60 (31.5%).
Conditioning regimens: myeloablative¼ 86 (45.3%), reduced
